Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease
- 1 December 1993
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 45 (5), 419-423
- https://doi.org/10.1007/bf00315512
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- The Effect of Catechol-O-Methyl Transferase Inhibition by Entacapone on the Pharmacokinetics and Metabolism of Levodopa in Healthy VolunteersClinical Neuropharmacology, 1993
- Liquid chromatographic determination of a new catechol-O-methyltransferase inhibitor, entacapone, and its Z-isomer in human plasma and urineJournal of Pharmaceutical and Biomedical Analysis, 1992
- Simultaneous determination of levodopa, its main metabolites and carbidopa in plasma by liquid chromatographyJournal of Pharmaceutical and Biomedical Analysis, 1991
- Rationale for Selective COMT Inhibitors as Adjuncts in the Drug Treatment of Parkinson's DiseaseBasic & Clinical Pharmacology & Toxicology, 1990
- Catechol‐O‐methyltransferase‐Inhibiting Pyrocatechol Derivatives: Synthesis and Structure‐Activity StudiesHelvetica Chimica Acta, 1989
- Clinical Pharmacokinetics of Anti-Parkinsonian DrugsClinical Pharmacokinetics, 1987
- 3‐O‐Methyldopa and the response to levodopa in Parkinson's diseaseAnnals of Neurology, 1987
- 3‐O‐ methyldopa blocks dopa metabolism in rat corpus striatumAnnals of Neurology, 1982
- IGPHARM: Interactive graphic package for pharmacokinetic analysisComputers and Biomedical Research, 1978
- 3-0-Methyldopa uptake and inhibition of L-dopa at the blood-brain barrierLife Sciences, 1975